Yield10 Bioscience Inc (NASDAQ:YTEN) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 44,400 shares, a decrease of 22.2% from the August 15th total of 57,100 shares. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.4% of the company’s shares are sold short.
Shares of NASDAQ YTEN opened at $7.25 on Thursday. Yield10 Bioscience has a 12-month low of $3.50 and a 12-month high of $31.05. The company has a market cap of $20.43 million, a P/E ratio of -0.34 and a beta of 2.55. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.40. The stock has a fifty day moving average price of $5.59 and a 200 day moving average price of $5.57.
Yield10 Bioscience (NASDAQ:YTEN) last announced its quarterly earnings results on Tuesday, August 11th. The specialty chemicals company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.30) by $0.38. Yield10 Bioscience had a negative return on equity of 347.89% and a negative net margin of 1,861.39%. On average, sell-side analysts forecast that Yield10 Bioscience will post -4.78 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Yield10 Bioscience stock. Virtu Financial LLC acquired a new stake in Yield10 Bioscience Inc (NASDAQ:YTEN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,246 shares of the specialty chemicals company’s stock, valued at approximately $64,000. Virtu Financial LLC owned about 0.52% of Yield10 Bioscience at the end of the most recent reporting period. 6.08% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently commented on YTEN. Zacks Investment Research downgraded Yield10 Bioscience from a “buy” rating to a “hold” rating in a report on Friday, September 4th. HC Wainwright began coverage on Yield10 Bioscience in a report on Thursday, September 10th. They set a “buy” rating and a $25.00 price objective for the company. National Securities upgraded Yield10 Bioscience from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Thursday, August 27th. Finally, Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Yield10 Bioscience in a report on Thursday, August 13th.
About Yield10 Bioscience
Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.
Recommended Story: Federal Reserve
Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.